Is metformin use associated with vitamin B12 deficiency?

Metformin therapy, a cornerstone of type 2 diabetes management, is associated with a clinically significant risk of developing vitamin B12 (cobalamin) deficiency, particularly in older adults who may already have compromised absorption pathways.

Clinical evidence

• Strong Association and Prevalence: Extensive clinical and observational evidence confirms a robust association between metformin use and vitamin B12 deficiency, with prevalence estimates reaching up to 27.7% in primary care cohorts.
• Dose and Duration Dependence: The risk of developing deficiency scales directly with treatment intensity. Higher daily doses (specifically exceeding 1,000 to 1,500 mg/day) and cumulative treatment durations extending beyond 1 to 5 years are strongly associated with progressive declines in serum cobalamin levels.

Mechanistic explanations

• Calcium-Dependent Malabsorption: Metformin induces B12 malabsorption by interfering with the calcium-dependent binding and uptake of the intrinsic factor-vitamin B12 (IF-B12) complex at the cubilin receptor in the terminal ileum.
• Reversibility: This specific inhibitory mechanism is highly characteristic of metformin therapy; supporting evidence shows that oral calcium supplementation can reverse metformin-induced B12 malabsorption, validating the calcium-dependent pathway.

Clinical implications

• Neurological Risks: Vitamin B12 deficiency is a known driver of peripheral neuropathy. In patients with type 2 diabetes, metformin-induced B12 deficiency can trigger or worsen neuropathic symptoms, which clinicians may mistakenly attribute solely to diabetic progression.
• Monitoring and Screening: Because B12 deficiency and its associated hematological and neurological symptoms develop gradually, regular or annual laboratory screening is highly recommended for patients on long-term or high-dose metformin.

Bottom line

• Metformin use is definitively associated with vitamin B12 deficiency caused by calcium-dependent ileal malabsorption. Periodic screening is essential, especially for older patients on high-dose or long-term therapy, to prevent the onset or worsening of irreversible peripheral neuropathy.